BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 29391527)

  • 1. High expression of SMARCA4 or SMARCA2 is frequently associated with an opposite prognosis in cancer.
    Guerrero-Martínez JA; Reyes JC
    Sci Rep; 2018 Feb; 8(1):2043. PubMed ID: 29391527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
    Karnezis AN; Wang Y; Ramos P; Hendricks WP; Oliva E; D'Angelo E; Prat J; Nucci MR; Nielsen TO; Chow C; Leung S; Kommoss F; Kommoss S; Silva A; Ronnett BM; Rabban JT; Bowtell DD; Weissman BE; Trent JM; Gilks CB; Huntsman DG
    J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation.
    Wilson BG; Helming KC; Wang X; Kim Y; Vazquez F; Jagani Z; Hahn WC; Roberts CW
    Mol Cell Biol; 2014 Mar; 34(6):1136-44. PubMed ID: 24421395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The SWI/SNF chromatin-remodeling complex status in renal cell carcinomas with sarcomatoid or rhabdoid features.
    Kinoshita F; Kohashi K; Sugimoto M; Takamatsu D; Kiyozawa D; Eto M; Oda Y
    Virchows Arch; 2020 Nov; 477(5):651-660. PubMed ID: 32447490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
    Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
    BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SWI/SNF Complex-deficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract: A Series of 13 Cases Highlighting Mutually Exclusive Loss of SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and SMARCA2.
    Agaimy A; Daum O; Märkl B; Lichtmannegger I; Michal M; Hartmann A
    Am J Surg Pathol; 2016 Apr; 40(4):544-53. PubMed ID: 26551623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of expression of SMARCA4 (BRG1), SMARCA2 (BRM) and SMARCB1 (INI1) in undifferentiated carcinoma of the endometrium is not uncommon and is not always associated with rhabdoid morphology.
    Ramalingam P; Croce S; McCluggage WG
    Histopathology; 2017 Feb; 70(3):359-366. PubMed ID: 27656868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients.
    Agaimy A; Amin MB; Gill AJ; Popp B; Reis A; Berney DM; Magi-Galluzzi C; Sibony M; Smith SC; Suster S; Trpkov K; Hes O; Hartmann A
    Hum Pathol; 2018 Jul; 77():139-146. PubMed ID: 29689242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switch/sucrose-non-fermentable (SWI/SNF) complex (SMARCA4, SMARCA2, INI1/SMARCB1)-deficient colorectal carcinomas are strongly associated with microsatellite instability: an incidence study in 4508 colorectal carcinomas.
    Ahadi MS; Fuchs TL; Clarkson A; Sheen A; Sioson L; Chou A; Gill AJ
    Histopathology; 2022 May; 80(6):906-921. PubMed ID: 34951482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors - a review of patent literature from 2019-30 June 2023.
    Reichl KD; Lee ECY; Gopalsamy A
    Expert Opin Ther Pat; 2024 Mar; 34(3):159-169. PubMed ID: 38578210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression inactivation of SMARCA4 by microRNAs in lung tumors.
    Coira IF; Rufino-Palomares EE; Romero OA; Peinado P; Metheetrairut C; Boyero-Corral L; Carretero J; Farez-Vidal E; Cuadros M; Reyes-Zurita FJ; Lupiáñez JA; Sánchez-Cespedes M; Slack FJ; Medina PP
    Hum Mol Genet; 2015 Mar; 24(5):1400-9. PubMed ID: 25355421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human cancer.
    Medina PP; Sanchez-Cespedes M
    Epigenetics; 2008; 3(2):64-8. PubMed ID: 18437052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
    Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
    Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type.
    Jelinic P; Schlappe BA; Conlon N; Tseng J; Olvera N; Dao F; Mueller JJ; Hussein Y; Soslow RA; Levine DA
    Mod Pathol; 2016 Jan; 29(1):60-6. PubMed ID: 26564006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens.
    Herpel E; Rieker RJ; Dienemann H; Muley T; Meister M; Hartmann A; Warth A; Agaimy A
    Ann Diagn Pathol; 2017 Feb; 26():47-51. PubMed ID: 28038711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SWI/SNF Complex-deficient Undifferentiated Carcinoma of the Gastrointestinal Tract: Clinicopathologic Study of 30 Cases With an Emphasis on Variable Morphology, Immune Features, and the Prognostic Significance of Different SMARCA4 and SMARCA2 Subunit Deficiencies.
    Chang B; Sheng W; Wang L; Zhu X; Tan C; Ni S; Weng W; Huang D; Wang J
    Am J Surg Pathol; 2022 Jul; 46(7):889-906. PubMed ID: 34812766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogene-dependent function of BRG1 in hepatocarcinogenesis.
    Wang P; Song X; Cao D; Cui K; Wang J; Utpatel K; Shang R; Wang H; Che L; Evert M; Zhao K; Calvisi DF; Chen X
    Cell Death Dis; 2020 Feb; 11(2):91. PubMed ID: 32019910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers.
    Papillon JPN; Nakajima K; Adair CD; Hempel J; Jouk AO; Karki RG; Mathieu S; Möbitz H; Ntaganda R; Smith T; Visser M; Hill SE; Hurtado FK; Chenail G; Bhang HC; Bric A; Xiang K; Bushold G; Gilbert T; Vattay A; Dooley J; Costa EA; Park I; Li A; Farley D; Lounkine E; Yue QK; Xie X; Zhu X; Kulathila R; King D; Hu T; Vulic K; Cantwell J; Luu C; Jagani Z
    J Med Chem; 2018 Nov; 61(22):10155-10172. PubMed ID: 30339381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinicopathological and molecular analysis of gastric cancer with altered SMARCA4 expression.
    Huang SC; Ng KF; Yeh TS; Cheng CT; Chen MC; Chao YC; Chuang HC; Liu YJ; Chen TC
    Histopathology; 2020 Aug; 77(2):250-261. PubMed ID: 32343857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological and prognostic significance of SWI/SNF complex subunits in undifferentiated gastric carcinoma.
    Zhang Z; Li Q; Sun S; Li Z; Cui ZG; Zhang M; Liu Q; Zhang Y; Xiong S; Zhang S
    World J Surg Oncol; 2022 Dec; 20(1):383. PubMed ID: 36464671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.